Previous 10 | Next 10 |
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo Phase 3 ORCA-2 Trial to Enroll 750 Smokers Acro...
Achieve Life Sciences (ACHV) promotes John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve's Chief Financial and Operating Officer since 2017.Rick Stewart, company's current Chairman and CEO, will continue as Executive Chairman.Additionally, Dr. ...
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President Canada NewsWire SEATTLE a...
Achieve Life Sciences ( ACHV +18.0% ) announced presentation of final results from the RAUORA trial evaluating the effectiveness and safety of cytisinicline compared to Pfizer's varenicline as a smoking cessation aid in 679 participants. Results were presented at the Society for Res...
SEATTLE and VANCOUVER, BC , Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced pr...
A study was conducted at the University of Cambridge Department of Biochemistry, was designed to examine the in vitro binding characteristics of Achieve Life Sciences' (NASDAQ: ACHV ) cytisinicline compared to varenicline at the human 5-HT 3 receptor (directly leads to naus...
SEATTLE , and VANCOUVER, British Columbia , Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced data prese...
The following slide deck was published by Achieve Life Sciences, Inc. in conjunction with this Read more ...
Lake Street initiated Achieve Life Sciences ( ACHV +11.0% ) with a Buy rating, PT $30; past 6 months the stock has generated 117%. More news on: Achieve Life Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SEATTLE and VANCOUVER, BC , Sept. 10, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that cytisinicline data w...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
2024-06-07 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today ann...
2024-05-27 04:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...